Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Hepatic ischemia-reperfusion (I/R) injury stands as a recurring clinical challenge in liver transplantation, leading to mitochondrial dysfunction and cellular imbalance. Mitochondria, crucial for hepatocyte metabolism, are significantly damaged during hepatic I/R and the extent of mitochondrial damage correlates with hepatocyte injury. PINK1/Parkin-mediated mitophagy, is a specialized form of cellular autophagy, that maintains mitochondrial quality by identifying and removing damaged mitochondria, thereby restoring cellular homeostasis. Taxifolin (TAX), a natural flavonoid, possesses antioxidant, anti-inflammatory and anticancer properties. This study aimed at investigating the effects of TAX on hepatic I/R and the underlying mechanisms.
Methods: C57BL/6 mice were pretreated with TAX or vehicle control, followed by 60 min of 70% hepatic ischemia. After 6 h of reperfusion, the mice were euthanized. In vitro, TAX-pretreated primary hepatocytes were subjected to oxygen glucose deprivation/reperfusion (OGD/R).
Results: Hepatic I/R caused mitochondrial damage and apoptosis in hepatocytes, but TAX pretreatment mitigated these effects by normalizing mitochondrial membrane potential and inhibiting reducing apoptotic protein expression. TAX exerted its protective effects by enhancing mitophagy via the PINK1/Parkin pathway. Moreover, silencing the PINK1 gene in primary hepatocytes reversed the beneficial effects of TAX.
Conclusion: The results of the study demonstrate that promoting mitophagy through the PINK1/Parkin pathway restores mitochondrial function and protects the liver from I/R, suggesting that it may have therapeutic potential for the treatment of hepatic I/R.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejphar.2024.177100 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MEF2D Aggravates Hepatic Ischaemia-Reperfusion Injury by Transcriptionally Regulating CXCL1 Through Interacting With NAT10.
Liver Int
September 2025
Hubei Key Laboratory of Medical Technology on Transplantation, Hubei Provincial Clinical Research Center for Natural Polymer Biological Liver, National Quality Control Center for Donated Organ Procurement, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University
Background And Aims: Hepatic ischaemia-reperfusion injury (IRI), a common complication after hepatectomy and liver transplantation (LT), is a local sterile inflammatory response driven by innate immunity. Myocyte enhancer factor-2D (MEF2D) plays an important role in immune inflammatory response by transcriptionally activating or inhibiting gene expression, which is tightly associated with the pathogenic progression of hepatic disorders. However, the role of MEF2D in hepatic IRI is still unclear.
View Article and Find Full Text PDFPhase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma.
J Hepatol
August 2025
Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain.
Background & Aims: Patients with advanced hepatocellular carcinoma (HCC) generally experience poor outcomes despite current therapies; alternative treatments are needed. ADP-A2AFP is an investigational autologous T-cell therapy with an affinity-enhanced T-cell receptor (TCR) targeting alpha-fetoprotein (AFP).
Methods: We describe a phase I, open-label, first-in-human clinical trial of ADP-A2AFP (NCT03132792) in human leukocyte antigen-eligible participants with AFP-expressing HCC (or other tumor) not amenable to transplant/resection that progressed on, were intolerant to, or refused prior systemic therapy.
Remifentanil Mitigates Hepatic Ischemia/Reperfusion-Induced D1-Medium Spiny Neurons Damage via Fibroblast Growth Factor 18 Upregulation.
Antioxid Redox Signal
July 2025
Department of Blood Transfusion, The 2nd Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China.
Hepatic ischemia/reperfusion (I/R) injury induces liver damage and secondary neuronal injury, particularly in D1-medium spiny neurons (D1-MSNs). This study investigates whether remifentanil exerts neuroprotective effect by regulating oxidative stress and inflammation fibroblast growth factor 18 (FGF18) upregulation. Remifentanil markedly attenuated liver and striatal injury in a murine I/R model, as indicated by decreased serum levels of alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, along with reduced inflammatory cytokines interleukin 1 beta and interleukin 18.
View Article and Find Full Text PDFAlleviative Effects of Ciprofol on Hepatic Ischemia/Reperfusion Injury Through Inhibiting Macrophage Polarization.
Immun Inflamm Dis
July 2025
Department of Surgical Anesthesiology, The First Hospital of Yulin, Yulin, China.
Background: Previous studies have demonstrated the protective role of ciprofol against ischemia/reperfusion (I/R) injury, with the present investigation focusing on elucidating its effects on hepatic I/R injury.
Methods: A hepatic I/R injury animal model was established, and macrophages were polarized using lipopolysaccharide (LPS) induction. Hepatic tissue damage and apoptosis were assessed through hematoxylin-eosin and TUNEL staining.
Bromodomain protein 4 inhibitor JQ-1 alleviates hepatic ischemia-reperfusion injury by blocking the NLRP3/caspase-1 pathway.
World J Emerg Med
July 2025
2Department of Surgery, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310052, China.
Background: Hepatic ischemia-reperfusion (I/R) injury is a major challenge in liver surgery and transplantation. Bromodomain protein 4 (BRD4) has emerged as a promising target due to its role in oxidative stress and inflammation. JQ-1, a specific BRD4 inhibitor, has shown protective effects on organs suffering I/R injury.
View Article and Find Full Text PDF